28243093|t|Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone
28243093|a|Drug delivery carriers can maintain effective therapeutic concentrations in the eye. To this end, we developed lipid nanoparticles (L / NPs) in which the surface was modified with positively charged chitosan, which engaged in hydrogen bonding with the phospholipid membrane. We evaluated in vitro corneal permeability and release characteristics, ocular irritation, and drug dynamics of modified and unmodified L / NPs in aqueous humor. The size of L / NPs was uniform and showed a narrow distribution. Corneal permeation was altered by the presence of chitosan and was dependent on particle size; the apparent permeability coefficient of dexamethasone increased by 2.7 and 1.8 times for chitosan - modified and unmodified L / NPs, respectively. In conclusion, a chitosan - modified system could be a promising method for increasing the ocular bioavailability of unmodified L / NPs by enhancing their retention time and permeation into the cornea. These findings provide a theoretical basis for the development of effective drug delivery systems in the treatment of ocular disease.
28243093	0	7	Corneal	T017	UMLS:C0010031
28243093	35	48	charged lipid	T103	UMLS:C0023779
28243093	62	69	carrier	T103	UMLS:C0013161
28243093	81	94	dexamethasone	T103	UMLS:C0011777
28243093	95	117	Drug delivery carriers	T103	UMLS:C0013161
28243093	175	178	eye	T017	UMLS:C0015392
28243093	206	211	lipid	T103	UMLS:C0023779
28243093	227	228	L	T103	UMLS:C0023779
28243093	249	256	surface	T082	UMLS:C0205148
28243093	294	302	chitosan	T103	UMLS:C0162969
28243093	347	359	phospholipid	T103	UMLS:C0031676
28243093	360	368	membrane	T103	UMLS:C0005479
28243093	392	399	corneal	T017	UMLS:C0010031
28243093	442	448	ocular	T017	UMLS:C0015392
28243093	449	459	irritation	T033	UMLS:C1706307
28243093	465	469	drug	T103	UMLS:C1254351
28243093	506	507	L	T103	UMLS:C0023779
28243093	517	530	aqueous humor	T031	UMLS:C0003662
28243093	536	540	size	T082	UMLS:C0456389
28243093	544	545	L	T103	UMLS:C0023779
28243093	584	596	distribution	T082	UMLS:C0037775
28243093	598	605	Corneal	T017	UMLS:C0010031
28243093	636	644	presence	T033	UMLS:C0150312
28243093	648	656	chitosan	T103	UMLS:C0162969
28243093	734	747	dexamethasone	T103	UMLS:C0011777
28243093	783	791	chitosan	T103	UMLS:C0162969
28243093	818	819	L	T103	UMLS:C0023779
28243093	858	866	chitosan	T103	UMLS:C0162969
28243093	906	912	method	T170	UMLS:C0025663
28243093	932	938	ocular	T017	UMLS:C0015392
28243093	969	970	L	T103	UMLS:C0023779
28243093	1035	1041	cornea	T017	UMLS:C0010031
28243093	1049	1057	findings	T033	UMLS:C0243095
28243093	1119	1140	drug delivery systems	T074	UMLS:C0085104
28243093	1148	1157	treatment	T058	UMLS:C0087111